Canon Medical Reinforces Commitment to AI Innovation With New Altivity Brand

Summation

  • Naoki Sasaki, Head of Research and Development, echoed these sentiments by saying that “Canon Medical's commitment to continued research and development has resulted in products that are establishing new standards in the area of AI in medicine and healthcare.
  • One of the most time-consuming aspects of an ultrasound exam is the care that must be taken to ensure serial measurements are done in a standardized and highly reproducible way.
  • Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.

Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.

Canon Medical has been steadily redefining the role of AI in healthcare, starting with its Advanced intelligent Clear-IQ Engine (AiCE). Initially developed for CT, this denoising deep learning technology was soon deployed across MRI and PET/molecular imaging to help speed up scan times and improve image quality. Next came the launch of Automation Platform and AUTOStroke solution, both of which were designed to enhance clinical confidence and streamline workflows with the power of deep learning technology.

More recently, Canon Medical has transformed the ultrasound space with AI innovations*, that revolutionize clinical workflows. One of the most time-consuming aspects of an ultrasound exam is the care that must be taken to ensure serial measurements are done in a standardized and highly reproducible way. By leveraging the power of AI, Canon Medical has been able to automate these routine tasks to increase clinical productivity and reporting accuracy.

Under the promise of Intelligent healthcare made easy, Altivity enables:

  • Informed healthcare
    Altivity is here to help enhance clinical confidence with high-quality images and applications that help make informed decisions in real time.
  • Fast, tailored care
    Altivity has been created with patients in mind, to deliver the fast and accurate results they need for a more personalized treatment approach.
  • Efficient workflows
    Altivity helps create simple, streamlined AI-driven workflows that optimize resource deployment and ensure your teams have the insights they need to work smarter every day.

Toshio Takiguchi, President and CEO of Canon Medical, says of the launch, “We are passionate about the development of intelligent imaging solutions that reflect the changing medical landscape. With Altivity, we are strengthening our focus to help clinicians leverage their data and transform it into essential insight that improves outcomes for everyone.”

Naoki Sasaki, Head of Research and Development, echoed these sentiments by saying that “Canon Medical’s commitment to continued research and development has resulted in products that are establishing new standards in the area of AI in medicine and healthcare.”

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy